Effect of polymyxin B-immobilized fiber hemoperfusion on serum high mobility group box-1 protein levels and oxidative stress in patients with acute respiratory distress syndrome

ASAIO Journal

Volumn 55, Issue 4, 2009, Pages 395-399

  Nakamura, Tsukasa ^a   Fujiwara, Nobuharu ^a   Sato, Eiichi ^a   Kawagoe, Yasuhiro ^a   Ueda, Yoshihiko ^b   Yamada, Shingo ^c   Koide, Hikaru ^d  

^a Shinmatsudo Central General Hospital   (Japan)

^b DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINO TEST CORPORATION   (Japan)

^d KOTO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE RESPIRATORY DISTRESS SYNDROME; BEFORE AND AFTER; CYTOKINES; F TREATMENT; FIBER TREATMENT; HEMOPERFUSION; HIGH-MOBILITY GROUPS; POLYMYXIN B; PROTEIN LEVEL;

BLOOD PRESSURE; FIBERS; RESPIRATORY MECHANICS;

BLOOD;

8 HYDROXYDEOXYGUANOSINE; ENDOTOXIN; HIGH MOBILITY GROUP B1 PROTEIN; POLYMYXIN B;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEMOPERFUSION; HUMAN; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RESPIRATORY DISTRESS; SEPSIS; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

AGED; ANTI-BACTERIAL AGENTS; BLOOD PRESSURE; DEOXYGUANOSINE; EDEMA; ENDOTOXINS; FEMALE; HEMOPERFUSION; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYMYXIN B; RESPIRATORY DISTRESS SYNDROME, ADULT; SEPSIS;

EID: 68849124837     PISSN: 10582916     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAT.0b013e3181a5290f     Document Type: Article

References (42)

1. Tsushima K, Kubo K, Yoshikawa S, et al: Effects of PMX-DHP treatment for patients with directly induced acute respiratory distress syndrome. Ther Apher Dial 1 1: 138-145, 2007 (Pubitemid 46449861)
2. Bosma KJ, LewisJF: Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs 12: 461-477, 2007 (Pubitemid 47518379)
3. Buttenschoen K, Kornmann M, Beger D, et al: Endotoxemia and endotoxin tolerance in patients with ARDS. Langenbecks Arch Surg 393: 473-478, 2008
4. Czura CJ, Wang H, Tracey KJ: Dual roles of HMGB1: DNA binding and cytokine. J Endotoxin Res 7: 315-321, 2001 (Pubitemid 33041072)
5. Voll RE, Urbonaviciute V, Herrmann M, Kalden JR: High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases. Isr Med Assoc J 10: 26-28, 2008 (Pubitemid 351649458)
6. Klune JR, Dhupar R, Cardinal J, et al: HMGB1 endogenous danger signaling. Mol Med 14: 476-484, 2008
7. Kimura S, Yamauchi H, Hibino Y, et al: Evaluation of urinary 8-hydroxydeoxyguanine in healthy Japanese people. Basic Clin Phamacol Toxicol 98: 496-502, 2006
8. Nakamura T, Kawagoe Y, Ueda Y, et al: Polymyxin B-immobilized fibre haemoperfusion reduces urinary 8-hydroxy-2'-deoxyguanosine levels in patients with septic shock. Clin Intens Care 17: 95-100, 2008
9. Nakamura T, Kawagoe Y, Suzuki T, et al: Changes in plasma IL-18 by direct hemoperfusion with polymyxin B-immobilized fiber in patients with septic shock. Blood Purif 23: 417-420, 2005 (Pubitemid 41816067)
10. Nakamura T, Suzuki T, Kawagoe Y, Koide H: Polymyxin Bimmobilized fiber hemoperfusion attenuates increased plasma atrial natriuretic peptide and brain natriuretic peptide levels in patients with septic shock. ASAIO J 54: 210-213, 2008
11. Tsushima K, Kubo K, Koizumi T, et al: Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome. JClin Apher 17: 97-102, 2002 (Pubitemid 34809559)
12. Bernard GR, Artigas A, Brigham KI, et al: The American-European Consensus Conference on ARDS. Definition, mechanisms, relevant outcomes and clinical trial coordination. Am J Respir Crit Care Med 149: 811-824, 1994 (Pubitemid 24082248)
13. Knaus W, Draper E, Wagner D, Zimmerman J: APACHE II: A severity of disease classification system. Crit Care Med 13: 818-829, 1985 (Pubitemid 15250137)
14. Vincent JL, de Mendonça A, Cantraine F: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med 26: 1 793-1800, 1998
15. Murray JF, Matthay MA, Luce JM, Flick MR: An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138: 720-723, 1988 (Pubitemid 18224322)
16. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B- immobilized fiber. Am J Surg 167: 412-41 7, 1994 (Pubitemid 24186181)
17. Shoji H, Tani T, Hanasawa K, Kodama M: Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application. Ther Apher 2: 3-12, 1998 (Pubitemid 28311178)
18. Kanaya S, Ikeya M, Yamamoto K, et al: Comparison of an oxidative stress biomarker "urinary 8-hydroxy-2'-deoxyguanosine" between smokers and non-smokers. Biofactors 22: 255-258, 2004
19. Saito S, Yamauchi H, Hasui Y, et al: Quantitative determination of urinary 8-hydroxydeoxyguanosine (8-OHdG) by using ELISA. Res Commun Mol Pathol Pharmacol 107: 39-44, 2000 (Pubitemid 32240566)
20. Yamada S, Inoue K, Yakabe K, et al: High mobility group protein-1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 49: 1535-1537, 2003 (Pubitemid 37011747)
21. Yamada S, Yakabe K, Ishii J, et al: New high mobility group box 1 assay system. Clin Chim Acta 372: 173-178, 2006 (Pubitemid 44286776)
22. Uriu K, Osajima A, Hiroshige K: Endotoxin removal by direct hemoperfusion with an adsorbent column using polymyxin B-immobilized fiber ameliorates systemic circulatory disturbance in patients with septic shock. Am J Kidney Dis 39: 937-947, 2002 (Pubitemid 34454212)
23. Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285: 248-251, 1999 (Pubitemid 29329996)
24. Liu KD, Matthay MA: Advances in critical care for the nephrologists: Acute lung injury/ARDS. Clin JAm Soc Nephrol 3: 578-586, 2008
25. Inoue K, Kawahara K, Biswas KK, et al: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 16: 136-143, 2007 (Pubitemid 46729668)
26. Lanchou J, Corbel M, Tanguy M, et al: Imbalance between matrix met alloproteinases (MMP-9 and MMP-2) and tissue inhibitors of met alloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 31: 536-542, 2003 (Pubitemid 36232952)
27. Youn JH, Oh YJ, Kim ES, et al: High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer oflipopolysac- charide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 180: 5067-5074, 2008
28. Van Zoelen MA, Laterre PF, van Veen SQ, et al: Systemic and local high mobility group box 1 concentrations during severe infection. Crit Care Med 35: 2799-2804, 2007 (Pubitemid 350175778)
29. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al: Persistent elevation ofhigh mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33: 564-573, 2005 (Pubitemid 40365558)
30. Gaini S, Pedersen SS, Koldkjaer OG, et al: High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: A prospective study. Crit Care 11: R32, 2007 (Pubitemid 46502187)
31. Sakamoto Y, Mashiko K, Matsumoto H, et al: Relationship between effect of polymyxin B-immobilized fiber and high mobility group box-1 protein in septic shock patients. ASAIO J 53: 324-328, 2007 (Pubitemid 46791540)
32. Fukuto JM, Hobbs AJ, Ignarro LJ: Conversion of nitroxyl (HNO) to nitric oxide (NO) in biological systems: The role of physiological oxidants and relevance to the biological activity of HNO. Biochem Biophys Res Commun 196: 707-713, 1993 (Pubitemid 23337665)
33. LangJD, McArdle PJ, O'Reilly PJ, Matalon S: Oxidant-antioxidant balance in acute lung injury. Chest 122: 314S-320S, 2002 (Pubitemid 36043021)
34. Wu LL, Chiou CC, Chang PY, Wu JT: Urinary 8-OHdG: A marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetes. Clin Chim Acta 339: 1-9, 2 004
35. Maeshima E, Liang XM, Goda M, et al: The efficacy of vitamin E against oxidative damage and autoantibody production in systemic lupus erythematosus: A preliminary study. Clin Rheumatol 26: 401-404, 2007 (Pubitemid 46486973)
36. Tsukahara H: Biomarkers for oxidative stress: Clinical application in pediatric medicine. Curr Med Chem 14: 339-351, 2007 (Pubitemid 46299700)
37. Li L, Shoji W, Takano H, et al: Increased susceptibility of MER5 (peroxiredoxin III) knockout mice to LPS-induced oxidative stress. Biochem Biophys Res Commun 355: 715-721, 2007 (Pubitemid 46330210)
38. Heyland DK, Dhaliwal R, Suchner U, Berger MM: Antioxidant mutriens: A systemic review of trace elements and vitamins in the critically ill patients. Intens Care Med 31: 327-337, 2005
39. Nathens AB, Neff MJ, Jurkovich GJ, et al: Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg 236: 814-822, 2002 (Pubitemid 35403237)
40. Abiles J, de la Cruz AP, Castano J, et al: Oxidative stress is increased in critically ill patients according to antioxidant vitamins intake, independent of severity: A cohort study. Crit Care 10: R146, 2006 (Pubitemid 47086947)
41. Sakamoto Y, Mashiko K, Obata T, et al: Effectiveness of continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter after polymyxin B-immobilized fiber column therapy of septic shock. ASAIO J 54: 129-132, 2008
42. Nakada TA, Oda S, Matsuda K, et al: Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med 14: 257-1163, 2008 (Pubitemid 351785698)